logo
Share SHARE
FONT-SIZE Plus   Neg

Mindray Medical Q4 Profit Rises - Quick Facts

Mindray Medical International Limited (MR) announced that its fourth quarter 2011 net income attributable to the Company was $46.8 million up from $41.0 million in the fourth quarter of 2010. Earnings per share were $0.40, up from $0.35 in the fourth quarter of 2010.

Non-GAAP net income increased 14.2% to $51.8 million from $45.4 million in the fourth quarter of 2010. Non-GAAP earnings per share were $0.44, compared to $0.38 in the fourth quarter of 2010.

Net revenues were $264.1 million for the fourth quarter of 2011, a 25.2% increase from $211.0 million in the fourth quarter of 2010.

Analysts polled by Thomson Reuters expected the company to report earnings of $0.41 per share on revenues of $249.17 million for the quarter. Analysts' estimates typically exclude special items.

Mindray's board has declared a cash dividend on its ordinary shares of $0.40 per share, based on the company's net income for the full year 2011. The cash dividend will be payable on or around April 10, 2012, to shareholders of record as of March 9, 2012.

The company expects its full year 2012 net revenues to grow at least 18% over its full year 2011 net revenues. The company also expects its full year 2012 non-GAAP net income to grow at least 13% over its non-GAAP net income for full year 2011. Analysts expect the company to report earnings of $1.69 per share on revenues of $1.03 billion for foscal 2012.

The company expects its capital expenditure for 2012 to be around $90 million.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Foodservice distributor Sysco Corp. (SYY) reported a third-quarter profit that grew 22.7 percent from last year, while quarterly sales increased 2.2 percent. Both earnings per share and revenue for the quarter beat analysts' expectations. Halliburton Co. (HAL) and Baker Hughes Inc. (BHI) announced Sunday that they terminated the merger agreement they entered into in November 2014, effective April 30, 2016. In connection with the termination of the merger agreement, Halliburton will pay Baker Hughes the termination fee of $3.5 billion... The bench to bedside journey of drugs is fraught with challenges. It is estimated that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and out of those 5, only 1 may pass through all the regulatory hurdles needed to reach pharmacy shelves.
comments powered by Disqus
Follow RTT